View Latest Medical and Pharma Bids and Tenders

Completion Of A Non-excl. Discount Agreement According To § 130c Para. 1 Sgb V To Mepolizumab Atc Code: R03dx09 For The Period From 03/01/2023 To 02/28/2025

Completion Of A Non-excl. Discount Agreement According To § 130a Para. 8 Sgb V On Fentanyl Dihydrogen Citrate, Atc Code: N02ab03 For The Period From 03/01/2023 To 02/28/2025

Completion of a non-excl. Discount agreement according to § 130c paragraph 1 SGB V for Elbasvir, Grazoprevir ATC code: J05AP54 for the period from 03/01/2023 to 02/28/2025

Conclusion of non-exclusive drug discount agreements according to § 130a Para. 8 SGB V by means of a so-called open house model for the active ingredient etanercept (ATC code according to WHO: L04AB01

Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V On The Active Ingredient Progesterone (exclusively Dosage Form Vka), Atc G03da04 For The Period 03/01/2023 - 02/28/20

Provision For Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V To The In Ii.2.4. Mentioned Active Substances With The Possibility Of Closing Within The Framework Of Th

Provision For Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V To The In Ii.2.4. Mentioned Active Substances With The Possibility Of Closing Within The Framework Of Th

Provision For Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V To The In Ii.2.4. Mentioned Active Substances With The Possibility Of Closing Within The Framework Of Th

Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V On The Active Ingredient Pipamperone, Atc N05ad05 For The Period 03/01/2023 - 02/28/2025

Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Bempedoic Acid + Ezetimibe, Atc C10ba10 For The Period 03/01/2023 - 02/28/2025